Neoleukin Therapeutics, Inc.
NLTXNASDAQHealthcare
$3.49
+$0.05(+1.45%)
Market Cap$8199685
P/E Ratio—
52W High$18.8
52W Low$3.42
Neoleukin Therapeutics, Inc. (NLTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NLTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.08B | $0.06B | $0.04B | $0.04B | $0.02B |
| G&A Expenses | $0.03B | $0.02B | $0.02B | $0.02B | $0.02B |
| Total Operating Expenses | $0.10B | $0.08B | $0.06B | $0.06B | $0.04B |
| Operating Income | ($0.10B) | ($0.08B) | ($0.06B) | ($0.06B) | ($0.03B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | ($0.00B) | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.09B) | ($0.08B) | ($0.06B) | ($0.06B) | ($0.03B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.01B) |
| Net Income | ($0.09B) | ($0.08B) | ($0.06B) | ($0.06B) | ($0.03B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.00 | $-3.96 | $-5.07 | $-5.31 | $-3.20 |
| Wtd Avg Shares | 0.00B | 0.02B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($0.10B) | ($0.08B) | ($0.05B) | ($0.06B) | ($0.05B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Neoleukin Therapeutics, Inc. data
About Neoleukin Therapeutics, Inc. (NLTX) Income Statement
Neoleukin Therapeutics, Inc. (NLTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NLTX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.09B) — a net profit margin of —.
Frequently asked questions
NLTX · 4 questionsNeoleukin Therapeutics, Inc. (NLTX) reported revenue of $0.00B for 2025, down —% year-over-year.
NLTX revenueNLTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09